等待开盘 07-08 09:30:00 美东时间
-0.006
-0.01%
An announcement from Fusion Finance Ltd ( ($IN:FUSION) ) is now available. Fusi...
06-24 20:23
KANSAS CITY, Mo., May 28, 2026 /PRNewswire/ -- American Century Investments, a $330 billion global asset manager*, expands its exchange traded fund (ETF) platform with the launch of American...
05-28 22:37
Fusion Finance Ltd ( ($IN:FUSION) ) just unveiled an update. Fusion Finance Lim...
04-07 05:33
BRIEF-Nuvation Bio Announces Acquisition Of Japan Rights To Safusidenib From Daiichi Sankyo April 1 (Reuters) - Koge Micro Tech Co Ltd 4568.TWO : NUVATION BIO ANNOUNCES ACQUISITION OF JAPAN RIGHTS TO SAFUSIDENIB FROM DAIICHI SANKYO NUVATION BIO INC - BUYS JAPAN RIGHTS TO SAFUSIDENIB FROM DAIICHI SAN
04-01 21:11
BRIEF-Nvidia Ai Ecosystem Expands As Marvell Joins Forces Through Nvlink Fusion March 31 (Reuters) - NVIDIA Corp NVDA.O : NVIDIA AI ECOSYSTEM EXPANDS AS MARVELL JOINS FORCES THROUGH NVLINK FUSION NVIDIA CORP - INVESTS $2 BILLION IN MARVELL NVIDIA CORP - CO AND MARVELL TO COLLABORATE ON SILICON PHOTO
03-31 20:30
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval March 27 (Reuters) - Sanofi SA SASY.PA : SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION ADMINISTERED VIA ON-BODY INJECTOR RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT MULTIPLE MYELOMA IF APPROVED, SARCL
03-27 20:03
BRIEF-Fusion Fuel Approves Appointment Of Uranium Investor James Passin To Board As Company Undertakes Uranium Royalty Strategy Fusion Fuel Green PLC HTOO.O : FUSION FUEL APPROVES APPOINTMENT OF URANIUM INVESTOR JAMES PASSIN TO BOARD AS COMPANY UNDERTAKES URANIUM ROYALTY STRATEGY Source text: ID:nGN
03-23 20:12
BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic March 17 (Reuters) - HCW Biologics Inc HCWB.O : HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE LICENSE FOR HCW11-006 – A HIGH POTENTIAL FUSION IMMUNOTHERAPEUTIC HCW BIOLOGICS INC - RECEIVES $7.
03-17 19:51
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile.
03-14 23:51
BRIEF-Sumitomo Corp - Investment In U.S.-Based Fusion Company Shine Technologies March 10 (Reuters) - Sumitomo Corp 8053.T : SUMITOMO CORP - INVESTMENT IN U.S.-BASED FUSION COMPANY SHINE TECHNOLOGIES Source text: [ID:] Further company coverage: 8053.T
03-10 09:04